{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:53:21Z","timestamp":1785873201099,"version":"3.56.0"},"reference-count":30,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"unspecified","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,11,19]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate\n                      <jats:sub>1,4,5<\/jats:sub>\n                      receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). While etrasimod demonstrated efficacy in randomised controlled trials, understanding its effectiveness in an observational setting is crucial.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>EFFECT-UC is a prospective, multinational, non-interventional study to evaluate the real-world effectiveness of etrasimod in adults with moderately to severely active UC. The study consists of a 52-week treatment period and a 28-day safety follow-up period and aims to enrol ~300 patients per cohort. Eligible patients (18\u201364 years) are advanced therapy na\u00efve or experienced and are initiating etrasimod in a real-world clinical setting. Treatment will be guided independently by the clinician\u2019s judgement. Patient-reported outcomes will be collected electronically throughout the study and daily for the first 2 weeks. Exploratory data, including faecal calprotectin, endoscopy and intestinal ultrasound, will be collected at predefined visits or during standard care. Primary endpoints are symptomatic remission at week 12 and week 52. Secondary endpoints include patient-reported outcome 2 (combined rectal bleeding and stool frequency subscores) response at week 12 and week 52 and corticosteroid-free symptomatic remission at week 52.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethics approval was obtained for all sites. Recruitment is underway for cohort 1, comprising patients from the UK, Germany and Canada. Interim results for this cohort are expected in 2026 and final results in 2028; these will be submitted for publication in peer-reviewed journals and presented at appropriate congresses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06294925\">NCT06294925<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-106141","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T06:10:27Z","timestamp":1766643027000},"page":"e106141","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of etrasimod on disease activity and patient-reported outcomes in ulcerative colitis\u2014EFFECT-UC: a non-interventional, multinational, prospective cohort study protocol"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct06294925","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06294925","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Gordon W","family":"Moran","sequence":"first","affiliation":[{"name":"School of Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shellie J","family":"Radford","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Walsh","sequence":"additional","affiliation":[{"name":"Translational Gastroenterology Unit, Oxford University Hospital, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Battat","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Centre Hospitalier de l\u2019Universit\u00e9 de Montreal, Montreal, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McLean","sequence":"additional","affiliation":[{"name":"Pfizer Ltd, Tadworth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kudela","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Binder","sequence":"additional","affiliation":[{"name":"Pfizer SLU, Alcobendas, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliia","family":"Kulchytska","sequence":"additional","affiliation":[{"name":"Pfizer Pharma GmbH, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Sahin","sequence":"additional","affiliation":[{"name":"Pfizer Ltd, Tadworth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Helwig","sequence":"additional","affiliation":[{"name":"Internistische Praxisgemeinschaft, Oldenburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0972-8148","authenticated-orcid":false,"given":"Peter M","family":"Irving","sequence":"additional","affiliation":[{"name":"IBD Unit, Guy\u2019s and St Thomas\u2019 Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"2026010703482517000_15.12.e106141.1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-030409-101225"},{"key":"2026010703482517000_15.12.e106141.2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx008"},{"key":"2026010703482517000_15.12.e106141.3","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.727"},{"key":"2026010703482517000_15.12.e106141.4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031"},{"key":"2026010703482517000_15.12.e106141.5","doi-asserted-by":"crossref","DOI":"10.1093\/crocol\/otad009","article-title":"Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis","volume":"5","author":"Panaccione","year":"2023","journal-title":"Crohn\u2019s Colitis 360"},{"key":"2026010703482517000_15.12.e106141.6","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1007\/s12325-023-02605-y","article-title":"Unmet Needs in Real-World Advanced Therapy-Na\u00efve and -Experienced Patients with Moderately to Severely Active Ulcerative Colitis in the United States","volume":"40","author":"Afzali","year":"2023","journal-title":"Adv Ther"},{"key":"2026010703482517000_15.12.e106141.7","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/ecco-jcc\/jjae060","article-title":"Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme","volume":"18","author":"Regueiro","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026010703482517000_15.12.e106141.8","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"2026010703482517000_15.12.e106141.9","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/ecco-jcc\/jjab016","article-title":"Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study","volume":"15","author":"Vermeire","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026010703482517000_15.12.e106141.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00061-2"},{"key":"2026010703482517000_15.12.e106141.11","doi-asserted-by":"crossref","first-page":"i184","DOI":"10.1093\/ecco-jcc\/jjae190.0091","article-title":"DOP052 Etrasimod as induction and maintenance therapy in Asian patients with moderately to severely active Ulcerative Colitis: Results from the maintenance period of a randomised, double-blind, placebo-controlled, multi-centre Phase 3 study (ES101002)","volume":"19","author":"Wu","year":"2025","journal-title":"J Crohn\u2019s Colitis"},{"key":"2026010703482517000_15.12.e106141.12","unstructured":"European Medicines Agency . VELSIPITY: summary of product characteristics, 2024. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/velsipity-epar-product-information_en.pdf"},{"key":"2026010703482517000_15.12.e106141.13","unstructured":"US Food and Drug Administration . VELSIPITY (etrasimod): highlights of prescribing information, 2024. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216956s001lbl.pdf"},{"key":"2026010703482517000_15.12.e106141.14","unstructured":"Medicines & Healthcare Products Regulatory Agency . VELSIPITY summary of product characteristics, 2024. Available: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/f23ffb5e0a19533545161a744983a9c2321bf195"},{"key":"2026010703482517000_15.12.e106141.15","unstructured":"Health Canada . VELSIPITY product monograph [online, 2024. Available: https:\/\/pdf.hres.ca\/dpd_pm\/00074415.PDF"},{"key":"2026010703482517000_15.12.e106141.16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/ecco-jcc\/jjac136","article-title":"Development of a Core Outcome Set for Real-world Data in Inflammatory Bowel Disease: A European Crohn\u2019s and Colitis Organisation [ECCO] Position Paper","volume":"17","author":"Hanzel","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026010703482517000_15.12.e106141.17","unstructured":"Canada\u2019s Drug and Health Technology Agency . Guidance for reporting real-world evidence, 2023. Available: https:\/\/www.cda-amc.ca\/sites\/default\/files\/RWE\/MG0020\/MG0020-RWE-Guidance-Report-Secured.pdf"},{"key":"2026010703482517000_15.12.e106141.18","unstructured":"US Food and Drug Administration . Ulcerative colitis: developing drugs for treatment, 2022. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/ulcerative-colitis-developing-drugs-treatment"},{"key":"2026010703482517000_15.12.e106141.19","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20520"},{"key":"2026010703482517000_15.12.e106141.20","doi-asserted-by":"crossref","DOI":"10.1093\/crocol\/otab007","article-title":"Full, Partial, and Modified Permutations of the Mayo Score: Characterizing Clinical and Patient-Reported Outcomes in Ulcerative Colitis Patients","volume":"3","author":"Naegeli","year":"2021","journal-title":"Crohn\u2019s & Colitis 360"},{"key":"2026010703482517000_15.12.e106141.21","doi-asserted-by":"crossref","DOI":"10.1093\/jcag\/gwae059.221","article-title":"A221 GENERALIZABILITY OF RANDOMIZED CONTROLLED TRIALS TO ROUTINE CLINICAL CARE IN ULCERATIVE COLITIS","volume":"8","author":"Chhibba","year":"2025","journal-title":"J Can Assoc Gastroenterol"},{"key":"2026010703482517000_15.12.e106141.22","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3079"},{"key":"2026010703482517000_15.12.e106141.23","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-319451"},{"key":"2026010703482517000_15.12.e106141.24","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/ecco-jcc\/jjz163","article-title":"Systematic Review: Clinical Utility of Gastrointestinal Ultrasound in the Diagnosis, Assessment and Management of Patients With Ulcerative Colitis","volume":"14","author":"Smith","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026010703482517000_15.12.e106141.25","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/ecco-jcc\/jjad071","article-title":"Early Intestinal Ultrasound Predicts Long-Term Endoscopic Response to Biologics in Ulcerative Colitis","volume":"17","author":"Allocca","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026010703482517000_15.12.e106141.26","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/ibd\/izad274","article-title":"Early Intestinal Ultrasound Predicts Clinical and Endoscopic Treatment Response and Demonstrates Drug-Specific Kinetics in Moderate-to-Severe Ulcerative Colitis","volume":"30","author":"de Voogd","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026010703482517000_15.12.e106141.27","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2358183","article-title":"Tofacitinib is an effective treatment for moderate to severe ulcerative colitis, and intestinal ultrasound can discriminate response from non-response: a pragmatic prospective real-world study","volume":"56","author":"Ollech","year":"2024","journal-title":"Ann Med"},{"key":"2026010703482517000_15.12.e106141.28","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/ecco-jcc\/jjab173","article-title":"Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease: Systematic Review and Expert Consensus Statement","volume":"16","author":"Ilvemark","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026010703482517000_15.12.e106141.29","doi-asserted-by":"crossref","DOI":"10.1093\/crocol\/otad043","article-title":"Integrating Intestinal Ultrasound into an Inflammatory Bowel Disease Practice: How to Get Started","volume":"5","author":"Abraham","year":"2023","journal-title":"Crohn\u2019s & Colitis 360"},{"key":"2026010703482517000_15.12.e106141.30","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.dld.2024.01.192","article-title":"The learning curve for using intestinal ultrasonography","volume":"56","author":"Bezzio","year":"2024","journal-title":"Dig Liver Dis"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-106141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T11:51:42Z","timestamp":1767786702000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-106141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,24]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjopen-2025-106141"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-106141","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}